Table 1:
Patient characteristics
| DOAC (N=1868) |
Warfarin (N=3758) |
Total (N=5626) |
|
|---|---|---|---|
|
| |||
| BMI kg/m2 | |||
|
| |||
| Mean (SD) | 40.0 (5.8) | 41.4 (7.2) | 41.0 (6.8) |
|
| |||
| BMI Category (kg/m2) | |||
|
| |||
| <35 | 45 (2.4%) | 90 (2.4%) | 135 (2.4%) |
|
| |||
| 35-<40 | 1138 (61.0%) | 2032 (54.1%) | 3170 (56.3%) |
|
| |||
| 40-<45 | 385 (20.6%) | 780 (20.8%) | 1165 (20.7%) |
|
| |||
| 45-<50 | 173 (9.3%) | 423 (11.3%) | 596 (10.6%) |
|
| |||
| ≥50 | 127 (6.8%) | 433 (11.5%) | 560 (10.0%) |
|
| |||
| Weight (kg)- mean (SD) * | 115.8 (21.7) | 119.0 (25.8) | 117.9 (24.5) |
|
| |||
| 120-140 kg | 720 (39.1%) | 1498 (41.8%) | 2218 (40.9%) |
|
| |||
| ≥ 140 kg | 230 (12.5%) | 586 (16.3%) | 816 (15.0%) |
|
| |||
| Age (years)- mean (SD) | 55.6 (15.0) | 58.4 (14.6) | 57.5 (14.8) |
|
| |||
| Sex- female | 1053 (56.4%) | 2172 (57.8%) | 3225 (57.3%) |
|
| |||
| Oral anticoagulant | |||
| Apixaban | 472 (25.3%) | ||
| Dabigatran | 52 (2.8%) | ||
| Edoxaban | 1 (0.1%) | ||
| Rivaroxaban | 1343 (71.9%) | ||
|
| |||
| Race Category | |||
|
| |||
| White | 1396 (74.7%) | 2674 (71.2%) | 4070 (72.3%) |
|
| |||
| Black | 342 (18.3%) | 817 (21.7%) | 1159 (20.6%) |
|
| |||
| Unknown/Other | 130 (7.0%) | 267 (7.1%) | 397 (7.1%) |
|
| |||
| Ethnic Category | |||
|
| |||
| Not Hispanic/Latin-X | 1719 (92.0%) | 3502 (93.2%) | 5221 (92.8%) |
|
| |||
| Hispanic/Latin-X | 104 (5.6%) | 181 (4.8%) | 285 (5.1%) |
|
| |||
| Other/Unknown | 45 (2.4%) | 75 (2.0%) | 120 (2.1%) |
|
| |||
| Insurance Category | |||
|
| |||
| Medicaid/Medicare | 880 (47.1%) | 2008 (53.4%) | 2888 (51.3%) |
|
| |||
| Private | 803 (43.0%) | 1108 (29.5%) | 1911 (34.0%) |
|
| |||
| Unknown/Other | 185 (9.9%) | 642 (17.1%) | 827 (14.7%) |
|
| |||
| Co-morbidities | |||
|
| |||
| CVD+ | 491 (26.3%) | 1386 (36.9%) | 1877 (33.4%) |
|
| |||
| Liver disease | 153 (8.2%) | 432 (11.5%) | 585 (10.4%) |
|
| |||
| Renal failure | 62 (3.3%) | 416 (11.1%) | 478 (8.5%) |
|
| |||
| Malignancy | 498 (26.7%) | 1010 (26.9%) | 1508 (26.8%) |
|
| |||
| Antiphospholipid syndrome | 56 (3.0%) | 163 (4.3%) | 219 (3.9%) |
*
missing N=197, 25 in DOAC and 172 in warfarin;
+
CVD= cardiovascular disease (coronary artery disease or peripheral vascular disease)